2015 GI Cancers Symposium - Friday
Read More
Andrew X. Zhu, MD, PhD, Massachusetts General Hospital Cancer Center, presenting "Abstract 232: Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated ?-fetoprotein (AFP) from the randomized phase III REACH study"
San Francisco, CA - 2015 Gastrointestinal Cancers Symposium : Andrew X. Zhu, MD, PhD, Massachusetts General Hospital Cancer Center, presenting "Abstract 232: Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated ?-fetoprotein (AFP) from the randomized phase III REACH study" during General Session 5: Viral Hepatitis in the Oncological Landscape at the Gastrointestinal Cancers Symposium 2015 here today, Friday January 16, 2015. The Symposium is supported by ASCO, the American Society of Clinical Oncology, ASTRO, The American Society of Radiation Oncology, SSO, Society of Surgical Oncology and the AGA Institute. Over 3,000 physicians, researchers and allied healthcare professionals are attending the meeting which is being held at the Moscone West center in San Francisco and features the latest Gastrointestinal Cancers research in the areas of basic and clinical science. Date: Friday January 16, 2015. Photo by © ASCO/Todd Buchanan 2015 Technical Questions: todd@medmeetingimages.com; Phone: 612-226-5154. GI15_DailyNews
